Overview
A. Longitude Capital is a private investment firm that focuses primarily on venture growth
investments in drug development, medical technology, and health solutions companies. The
Firm was established in 2006 and operates from offices in Menlo Park, California, Greenwich,
Connecticut, and Boston, Massachusetts. Longitude Capital serves as an investment adviser
to pooled investment vehicles (the “Funds” or “Clients,” and each a “Fund” or “Client”) that
are exempt from registration under the Investment Company Act of 1940, as amended (the
“Investment Company Act”). The Firm’s principal owners are Juliet Tammenoms Bakker and
Patrick Enright.
B. Longitude Capital provides investment advisory services solely to the Funds with respect to
the identification, acquisition, management and disposition of, primarily, venture growth
investments in drug development, medical technology, and health
solutions companies
pursuant to management services agreements between Longitude Capital, the Funds and the
general partner entities of each Fund (the “GP Entity” or “GP Entities”).
C. Each Fund has a specific investment focus. The confidential offering materials, governing
documents, and contractual side letters of each Fund set forth these specific guidelines and
restrictions, which include, among other things, limits on the size, concentration, geography,
and type of security of the Fund’s underlying portfolio investments. Investors in the Funds
(the “Investors”) do not have the ability to impose specific investment objectives or
restrictions on the Funds.
D. The Firm does not participate in wrap fee programs.
E. As of March 29, 2024, Longitude Capital managed $1,671,277,000 in Clients’ assets on a
discretionary basis
0F
1 and $0 on a non-discretionary basis.